{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T14:38:31Z","timestamp":1768747111661,"version":"3.49.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002648","name":"Catholic University of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["RS-2023-00209312"],"award-info":[{"award-number":["RS-2023-00209312"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.atherosclerosis.2024.118549","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T06:57:44Z","timestamp":1722581864000},"page":"118549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["CRISPR\/Cas9-mediated suppression of A4GALT rescues endothelial cell dysfunction in a fabry disease vasculopathy model derived from human induced pluripotent stem cells"],"prefix":"10.1016","volume":"397","author":[{"given":"Yoo Jin","family":"Shin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Yun","family":"Chae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanbi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianying","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Woo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang In","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul Woo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0048-5717","authenticated-orcid":false,"given":"Byung Ha","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2024.118549_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.23876\/j.krcp.22.087","article-title":"Frequency of Fabry disease in chronic kidney disease patients including patients on renal replacement therapy in Korea","volume":"43","author":"Cho","year":"2024","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.23876\/j.krcp.23.125","article-title":"Screening and diagnosis of Fabry disease in chronic kidney disease: the important role of globotriaosylsphingosine","volume":"43","author":"Shin","year":"2024","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib3","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3892\/ijmm.2012.1139","article-title":"Possible role of transforming growth factor-beta1 and vascular endothelial growth factor in Fabry disease nephropathy","volume":"30","author":"Lee","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.23876\/j.krcp.20.264","article-title":"Fabry disease exacerbates renal interstitial fibrosis after unilateral ureteral obstruction via impaired autophagy and enhanced apoptosis","volume":"40","author":"Chung","year":"2021","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib5","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1161\/HYPERTENSIONAHA.112.195685","article-title":"Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine","volume":"60","author":"Rombach","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/ATVBAHA.113.302744","article-title":"Globotriaosylceramide induces endothelial dysfunction in fabry disease","volume":"34","author":"Satoh","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2215\/CJN.09480819","article-title":"The changing landscape of fabry disease","volume":"15","author":"Svarstad","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib8","doi-asserted-by":"crossref","first-page":"611","DOI":"10.23876\/j.krcp.21.056","article-title":"Fabry nephropathy before and after enzyme replacement therapy: important role of renal biopsy in patients with Fabry disease","volume":"40","author":"Kim","year":"2021","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib9","doi-asserted-by":"crossref","first-page":"628","DOI":"10.23876\/j.krcp.22.235","article-title":"A questionnaire survey on the diagnosis and treatment of Fabry nephropathy in clinical practice","volume":"42","author":"Choi","year":"2023","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.03.063","article-title":"A targeted multi-omic analysis approach measures protein expression and low-abundance transcripts on the single-cell level","volume":"31","author":"Mair","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib11","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","article-title":"Clinical benefit of enzyme replacement therapy in Fabry disease","volume":"69","author":"Breunig","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib12","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib14","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(15)60206-9","article-title":"Eliglustat for Gaucher's disease: trippingly on the tongue","volume":"385","author":"Hughes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib15","first-page":"25","article-title":"CRISPR\/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model","author":"Cui","year":"2023","journal-title":"Transl. Res."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib16","doi-asserted-by":"crossref","first-page":"698","DOI":"10.23876\/j.krcp.20.252","article-title":"Modeling of endothelial cell dysfunction using human induced pluripotent stem cells derived from patients with end-stage renal disease","volume":"40","author":"Kim","year":"2021","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.biomaterials.2018.11.032","article-title":"A combined hiPSC-derived endothelial cell and in vitro microfluidic platform for assessing biomaterial-based angiogenesis","volume":"194","author":"Natividad-Diaz","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12967-023-03992-0","article-title":"Modeling of Fabry disease nephropathy using patient derived human induced pluripotent stem cells and kidney organoid system","volume":"21","author":"Cui","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2021.102214","article-title":"Human-induced pluripotent stem cell lines (CMCi006-A and CMCi007-A) from a female and male patient with Fabry disease carrying the same frameshift deletion mutation","volume":"51","author":"Cui","year":"2021","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib20","first-page":"130","article-title":"Targeted PMP22 TATA-box editing by CRISPR\/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice","volume":"48","author":"Lee","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41536-021-00198-0","article-title":"SUPT4H1-edited stem cell therapy rescues neuronal dysfunction in a mouse model for Huntington's disease","volume":"7","author":"Park","year":"2022","journal-title":"NPJ Regen Med"},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/2050312120966456","article-title":"Long-term single-cell passaging of human iPSC fully supports pluripotency and high-efficient trilineage differentiation capacity","volume":"8","author":"Cruvinel","year":"2020","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1186\/s13287-020-01903-4","article-title":"Stepwise differentiation and functional characterization of human induced pluripotent stem cell-derived choroidal endothelial cells","volume":"11","author":"Mulfaul","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib24","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2009-07-233478","article-title":"Vascular endothelial growth factor activation of endothelial cells is mediated by early growth response-3","volume":"115","author":"Suehiro","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib25","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/aps.2013.2","article-title":"Characterization of a novel curcumin analog P1 as potent inhibitor of the NF-kappaB signaling pathway with distinct mechanisms","volume":"34","author":"Peng","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib26","first-page":"613","article-title":"The role of local renin-angiotensin system on high glucose-induced cell toxicity, apoptosis and reactive oxygen species production in PC12 cells","volume":"17","author":"Shahveisi","year":"2014","journal-title":"Iran J Basic Med Sci"},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib27","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/01.RES.87.10.840","article-title":"Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress","volume":"87","author":"Cai","year":"2000","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2013.03.004","article-title":"A systematic review to evaluate the effectiveness of carnitine supplementation in improving walking performance among individuals with intermittent claudication","volume":"229","author":"Delaney","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.642352","article-title":"Notch signaling in vascular endothelial cells, angiogenesis, and tumor progression: an update and prospective","volume":"9","author":"Akil","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib30","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0002-9440(10)64807-9","article-title":"Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo","volume":"157","author":"Salani","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.660843","article-title":"Mitochondrial CHCHD2: disease-associated mutations, physiological functions, and current animal models","volume":"13","author":"Kee","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib32","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.bbrc.2007.03.046","article-title":"Expression and initial characterization of human ALDH3B1","volume":"356","author":"Marchitti","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib33","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"alpha-Galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib34","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3727\/096368916X694265","article-title":"Imbalanced production of reactive oxygen species and mitochondrial antioxidant SOD2 in fabry disease-specific human induced pluripotent stem cell-differentiated vascular endothelial cells","volume":"26","author":"Tseng","year":"2017","journal-title":"Cell Transplant."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102633","article-title":"Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells","volume":"52","author":"Do","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib36","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1681\/ASN.2019050497","article-title":"Accumulation of globotriaosylceramide in podocytes in fabry nephropathy is associated with progressive podocyte loss","volume":"31","author":"Najafian","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib37","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.metabol.2016.09.007","article-title":"Endothelial progenitor cells from human fetal aorta cure diabetic foot in a rat model","volume":"65","author":"Zhao","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib38","doi-asserted-by":"crossref","DOI":"10.3791\/51312-v","article-title":"Endothelial cell tube formation assay for the in vitro study of angiogenesis","author":"DeCicco-Skinner","year":"2014","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib39","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s40265-021-01621-y","article-title":"Mechanisms of neutralizing anti-drug antibody formation and clinical relevance on therapeutic efficacy of enzyme replacement therapies in fabry disease","volume":"81","author":"Lenders","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib40","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib41","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0968-0004(00)01595-4","article-title":"p38 MAP kinases: beyond the stress response","volume":"25","author":"Nebreda","year":"2000","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib43","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.biopha.2018.07.107","article-title":"The protective effects of a novel synthetic beta-elemene derivative on human umbilical vein endothelial cells against oxidative stress-induced injury: involvement of antioxidation and PI3k\/Akt\/eNOS\/NO signaling pathways","volume":"106","author":"Ahmad","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phymed.2018.05.005","article-title":"Lespedeza cuneata protects the endothelial dysfunction via eNOS phosphorylation of PI3K\/Akt signaling pathway in HUVECs","volume":"48","author":"Lee","year":"2018","journal-title":"Phytomedicine"},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib45","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jvs.2005.01.020","article-title":"Differential effects of orbital and laminar shear stress on endothelial cells","volume":"41","author":"Dardik","year":"2005","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5758\/vsi.2015.31.2.33","article-title":"Different effects of orbital shear stress on vascular endothelial cells: comparison with the results of in vivo study with rats","volume":"31","author":"Kim","year":"2015","journal-title":"Vasc Specialist Int"},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib47","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1152\/japplphysiol.00138.2006","article-title":"Impaired shear stress-induced nitric oxide production through decreased NOS phosphorylation contributes to age-related vascular stiffness","volume":"101","author":"Soucy","year":"2006","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib48","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s12276-021-00683-y","article-title":"Human kidney organoids reveal the role of glutathione in Fabry disease","volume":"53","author":"Kim","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.atherosclerosis.2024.118549_bib49","article-title":"Reversal of the inflammatory responses in fabry patient iPSC-derived cardiovascular endothelial cells by CRISPR\/Cas9-Corrected mutation","volume":"22","author":"Song","year":"2021","journal-title":"Int. J. Mol. Sci."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024011171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024011171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T13:54:58Z","timestamp":1727704498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915024011171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":49,"alternative-id":["S0021915024011171"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.118549","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRISPR\/Cas9-mediated suppression of A4GALT rescues endothelial cell dysfunction in a fabry disease vasculopathy model derived from human induced pluripotent stem cells","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.118549","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118549"}}